Skip to main content

Table 2 Comparison of different patient groups according to their genotype respect to PFS and drug response

From: SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients

 

Number of patients

(n=)

Median PFS

(days)

Total patients

33

211

SMAD4 mut

8

90

SMAD4 wt

25

250

NF1 mut

4

53.5

NF1 wt

29

211

SMAD4mut or NF1mut

10

90

SMAD4wt and NF1wt

23

250

KRAS mut

9

99

KRAS wt

24

230.5

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us